Integra LifeSciences to Present at Healthcare Conference in May 2018

PLAINSBORO, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in May:

• On Tuesday, May 15, 2018 at 10:40 a.m. PT, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, NV. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com. 
• On Monday, May 21, 2018 at 11:30 a.m. ET, Sravan Emany, vice president, treasurer and investor relations, will present at the 2018 UBS Global Healthcare Conference in New York, NY.

About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, CertasTM, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest news and information about Integra and its brands, please visit www.integralife.com.

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contacts: Sravan Emany Vice President, Treasury & Investor Relations (609) 936-2488 [email protected] Michael Beaulieu Director, Investor Relations (609) 750-2827 [email protected] Media Contact: Laurene Isip Senior Director, Global Corporate Communications (609) 750-7984 [email protected]

Source: Integra LifeSciences Holdings Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Andersen prices secondary offering of 4.28M shares at $44 each
• Edesa Biotech prices $25M public offering on Nasdaq
• Saba Capital renames closed-end funds ETF, ticker unchanged